Crescent Biopharma Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Crescent Biopharma stock has a consensus rating of "Strong Buy" and an average price target of $29.43. The average 1-year stock price forecast is 58.65% higher than the current stock price, while the lowest is $22 (+18.60%) and the highest is $35 (+88.68%).

Price Target: $29.43 (+58.65%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$22	$29.43	$30	$35
Change	+18.60%	+58.65%	+61.73%	+88.68%

* Price targets were last updated on Mar 2, 2026.

Analyst Ratings

The average analyst rating for Crescent Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	3	4	4	4	4	4
Buy	2	2	2	2	2	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	6	6	6	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $25 → $22	Strong Buy	Maintains	$25 → $22	+18.60%	Mar 2, 2026
Brad Canino Guggenheim	Guggenheim	Strong Buy Initiates $35	Strong Buy	Initiates	$35	+88.68%	Jan 21, 2026
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $25	Strong Buy	Reiterates	$25	+34.77%	Aug 27, 2025
Akash Tewari Jefferies	Jefferies	Strong Buy Initiates $26	Strong Buy	Initiates	$26	+40.16%	Aug 25, 2025
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $25	Strong Buy	Initiates	$25	+34.77%	Aug 11, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

1.86M

from 10.84M

-82.81%

from 10.84M

Revenue Next Year

5.70M

from 1.86M

205.53%

from 1.86M

EPS This Year

-3.44

from -12.81

EPS Next Year

-3.18

from -3.44

Fiscal Year	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028	FY 2029	FY 2030
Period Ending	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027	Dec 31, 2028	Dec 31, 2029	Dec 31, 2030
Revenue	-	10.84M	1.86M	5.70M	6.97M	34.58M	104.99M
Revenue Growth	-	-	-82.81%	205.53%	22.39%	396.10%	203.63%
EPS	-93.11	-12.81	-3.44	-3.18	-3.73	-4.62	-4.03
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	10	9	9	5	5

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	9.0M	23.6M
Avg	1.9M	5.7M
Low	n/a	n/a

Revenue Growth

Revenue Growth	2026	2027
High	-17.3%	1,167.4%
Avg	-82.8%	205.5%
Low	-	-

EPS Forecast

EPS	2026	2027
High	-3.06	-2.63
Avg	-3.44	-3.18
Low	-4.23	-3.76

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.